Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MEDRELEAF CORP T.LEAF

"MedReleaf Corp is engaged in the production and sale of cannabis for medical purposes as regulated by the ACMPR, pursuant to its Licences and, in particular, its Markham Commercial Licence."


TSX:LEAF - Post by User

Comment by GoBlue2016on Jun 11, 2017 5:55pm
56 Views
Post# 26350558

RE:Just did some homework on LEAF...

RE:Just did some homework on LEAF...
richc3 wrote:
Started a position in LEAF earlier in the day -- anyone else? While researching also came across this interesting tidbit...
 
> LEAF is one of the industry leaders in Canada. For the quarter ended December 2016, reported sales were C$10.4 million. By comparison, generally accepted leader Canopy Growth (OTCPK:TWMJF) reported sales of C$9.0 million for the same quarter. But WEED's acquisition of Mettrum Health closed in January 2017 so they probably retain the title of 'king of the hill'. But LEAF is a leader with a reported 19% market share in August 2016 and reports a monthly market share of 15% to 20%.
 
Check out these numbers for December: https://i.imgur.com/tqe8IlE.png
 
Long SEDAR document with tons of information: https://www.sedar.com/CheckCode.do;jsessionid=0000t-rEEonb339VV14OyqTRGnT:188setvlh


lots of info. 

Metrics largely better than CGC as at Dec/16. 

The two I want watch before entering is: price per gram and usage per patient. 

They have lots of vets that will be affected by VAC decision to reduce their reimbursement to $8.50/gram (Nov/16) and reduction to from 10/gram to 3/grams a day (May/17).  

Aphria noted the first in their flat sales for last Q. 

Interesting company. 

GoBlue


<< Previous
Bullboard Posts
Next >>